Car-t cells for relapsed lymphoma and multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment called BAFF CAR-T cells for people with certain types of lymphoma or multiple myeloma that have come back or not responded to standard treatments. The treatment uses your own immune cells, modified in the lab to find and attack cancer cells, and is given as an infusion. The goal is to see if this can help control the disease when other options haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need a diagnosis of B-cell lymphoma (like diffuse large B-cell, follicular, or mantle cell) or multiple myeloma that has come back or not responded to previous treatments.
- For lymphoma: you should have tried at least 2 prior treatments, or your cancer grew within 6 months of your last chemo, or it came back within a year of a stem cell transplant.
- For multiple myeloma: you need to have tried at least 3 prior treatments, including certain types of therapy.
- You must have at least one measurable tumor (a tumor that can be seen on scans).
- Your cancer must not be in the brain or spinal cord.
- You should be in fairly good health otherwise (able to do daily activities, with adequate heart, lung, liver, and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
This trial tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack a protein called BAFF-R on your lymphoma cells. It is for people with certain types of B-cell lymphoma that have not responded well to at least two earlier treatments.
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
Hear when a new Non-Hodgkin Lymphoma Refractory/ Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.